Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ANVS
ANVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANVS News
Annovis Bio Secures Financing for Alzheimer's Drug Development
Apr 10 2026
Newsfilter
Annovis Bio Prices Underwritten Offering for $10 Million
Apr 09 2026
Newsfilter
Biotech IPOs Show Strong Performance in Q1 2026
Apr 08 2026
Newsfilter
Annovis Bio and Vale Executives Increase Stock Holdings
Apr 06 2026
NASDAQ.COM
Annovis Bio Secures New Patent, Shares Rise 17%
Apr 06 2026
NASDAQ.COM
Annovis Bio Secures New Patent for Buntanetap
Apr 02 2026
Newsfilter
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring
Mar 19 2026
Globenewswire
Annovis Biopress Reports FY GAAP EPS of -$1.40
Mar 16 2026
seekingalpha
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
Annovis to Conduct 36-Month Extension Study for Further Assessment of Buntanetap in Parkinson's Disease
Dec 19 2025
NASDAQ.COM
Annovis Initiates 36-Month Study for Parkinson's Drug Buntanetap
Dec 18 2025
Newsfilter
Annovis Bio to Host Webinar on Clinical Progress and Future Directions
Dec 16 2025
Newsfilter
Insider Buying Update for Friday, December 12: ANVS, ECL
Dec 12 2025
NASDAQ.COM
Annovis Bio Presents Parkinson's Disease Therapy Data at PSG Annual Meeting
Dec 03 2025
Newsfilter
U.S. Anti-Aging Products Market Driven by Longevity Health Expected to Hit $27 Billion by 2033
Nov 18 2025
Newsfilter
Annovis Bio Shares Surge Following New Data Indicating Buntanetap Prevents Cognitive Decline in Parkinson's Patients
Nov 17 2025
Benzinga
Show More News
